Efficacy and Safety of Retinol Palmitate Ophthalmic Solution in the Treatment of Dry Eye: A Japanese Phase II Clinical Trial [Corrigendum]

Toshida H, Funaki T, Ono K, et al. *Drug Des Devel Ther*. 2017;11:1871–1879

The authors have advised there are some mistakes in the mean changes and standard errors of the paper:

- 1. The standard errors of groups Placebo and VApal were all the same value for staining and symptom scores in Figure 1 (on page 1875) and Figure 3 (on page 1876), and Table 3 (on page 1877).
- 2. There were slight discrepancies in the Mean changes of Placebo group at 1, 2 and 4 weeks in Figure 3D.
- 3. There was a slight discrepancy in the Mean change of foreign body sensation in Placebo group at 1 week in Table 3.

- 1. The standard error listed in a different table on the statistical analysis software was adopted.
- 2. There were typing errors when transferring numerical values from statistical analysis software to graph creation software.
- 3. There was a mistake when rounding numerical value.

Since the statistical analysis had been performed using the original mean values (correct values), all results do not change.

The authors apologize for these errors and advise they do not affect the results of the paper.

The updated Figures and Table are shown below.

The authors have advised the errors were due to:





Figure I Mean change in staining score.

Notes: Mean change in fluorescein staining score (Δ) and RB staining score (Β) from baseline to

Notes: Mean change in fluorescein staining score (A) and RB staining score (B) from baseline to 1, 2, and 4 weeks. *P<0.05. **P<0.01 versus placebo (unpaired t-test). Abbreviations: RB, rose bengal; VApal, retinol palmitate.

Toshida et al Dovepress



 $\textbf{Figure 3} \ \ \text{Mean change in symptom score}.$ Notes: Mean change in symptom scores for dryness (A), blurred vision (B), heaviness (C), itching (D), and eye discharge (E) and total score for subjective symptoms (F) from baseline to 1, 2, and 4 weeks. *P<0.05. **P<0.01 versus placebo (unpaired t-test). Abbreviation: VApal, retinol palmitate.

Dovepress

Table 3 Mean Change in Symptom Score

	Week	Mean Change		P-value
		Placebo	VApal	
Dryness	1	-0.45±0.10	-0.73±0.12	0.0794
	2	−0.64±0.11	-0.79±0.14	0.3957
	4	-0.82±0.13	-0.91±0.13	0.6224
Eye fatigue	1	-0.33±0.12	-0.30±0.10	0.8483
	2	-0.48±0.12	-0.39±0.12	0.5923
	4	-0.55±0.11	-0.58±0.14	0.8629
Foreign body sensation	1	-0.09±0.13	-0.30±0.14	0.2780
	2	-0.36±0.13	-0.33±0.13	0.8683
	4	-0.33±0.14	-0.42±0.16	0.6693
Blurred vision	1	0.06±0.07	-0.36±0.10	0.0016
	2	0.03±0.07	-0.33±0.15	0.0299
	4	-0.21±0.11	-0.48±0.14	0.1321
Eye pain	1	-0.27±0.16	-0.21±0.09	0.7506
	2	-0.45±0.16	-0.24±0.12	0.2813
	4	-0.48±0.17	-0.33±0.16	0.5258
Photophobia	1	-0.06±0.10	-0.15±0.08	0.4646
	2	-0.09±0.09	-0.18±0.11	0.5276
	4	-0.18±0.12	-0.21±0.08	0.8359
Heaviness	1	0.00±0.11	-0.24±0.12	0.1277
	2	-0.09±0.12	-0.24±0.14	0.4199
	4	-0.39±0.11	-0.52±0.14	0.5025
Itching	1	-0.06±0.10	-0.24±0.10	0.1905
	2	-0.06±0.10	-0.36±0.12	0.0556
	4	-0.21±0.10	-0.36±0.13	0.3652
Ocular discomfort	1	-0.27±0.14	-0.24±0.14	0.8806
	2	-0.33±0.10	-0.27±0.14	0.7284
	4	-0.42±0.14	-0.55±0.13	0.5369
Eye discharge	1	-0.06±0.04	-0.12±0.10	0.5923
	2	-0.09±0.07	−0.27±0.11	0.1600
	4	-0.15±0.06	-0.33±0.09	0.1137
Tearing	1	-0.06±0.04	-0.15±0.06	0.2369
	2	-0.09±0.07	-0.12±0.07	0.7593
	4	-0.06±0.07	-0.12±0.10	0.6384
Hyperemia	1	0.00±0.06	-0.06±0.12	0.6602
	2	-0.06±0.10	-0.03±0.13	0.8551
	4	-0.21±0.10	-0.12±0.12	0.5719
Total score of the subjective symptoms	1	-0.82±0.32	-I.76±0.30	0.0351
	2	-I.52±0.3I	-I.88±0.39	0.4695
	4	-2.03±0.44	-2.36±0.45	0.5983

Abbreviation: VApal, retinol palmitate.

Toshida et al Dovepress

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also

been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/drug-design-development-and-therapy-journal

Dovepress